Phase 3 trial of [177Lu]Lu-DOTA-TATE, a somatostatin receptor-targeted radioligand therapy.

This study evaluates the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide LAR versus octreotide LAR alone as first-line treatment in newly diagnosed patients with well-differentiated, somatostatin receptor positive advanced gastroenteropancreatic NETs (Grade 1-2). Conducted in Fayetteville under Novartis oversight, the trial employs a randomized, open-label design to compare combination versus standard therapy.